Group 1 - Yunnan Baiyao plans to invest 137 million yuan in the second phase of its oral liquid project to meet growing market demand for its products [1] - Hanma Technology's subsidiary intends to increase capital by 575 million yuan in Shanghai Suoda and transfer 100% of its shares for 485 million yuan [2] - JiaoKong Technology won a contract worth 16.8 million euros for a project in Turkey, expected to be operational by December 2028 [3] Group 2 - Hanhui Technology's shareholder plans to reduce their stake by up to 1.86% [4] - Haisheng Pharmaceutical reported a 32.72% increase in revenue and a 36.89% increase in net profit for 2025 [5] - Oukang Pharmaceutical's net profit for 2025 decreased by 48.21% despite a 7.73% increase in revenue [6] Group 3 - Huaihe Energy expects a net profit of 1.684 to 1.784 billion yuan for 2025, a year-on-year increase of 96.31% to 107.97% [7] - Watson Bio received approval for clinical trials of its varicella vaccine [8] - ShunNa Co. plans to reduce its stake by up to 1% [9] Group 4 - Chutianlong intends to raise up to 760 million yuan through a private placement [10] - Yifang Technology's shareholders plan to reduce their holdings by up to 34,830 shares [12] - Yunjigroup's subsidiary signed an EPC contract worth 1.331 billion yuan [13] Group 5 - Jianghuai Automobile reported a 2.14% decrease in January sales [15] - Lifan Pharmaceutical participated in a national procurement program and aims to be selected for three products [16] - Magu Technology's shareholder plans to reduce their stake by up to 3% [17] Group 6 - Jianghuai Automobile's private placement raised approximately 3.5 billion yuan, with investor Ge Weidong subscribing for 1 billion yuan [18] - Huichuan Technology expects a net profit increase of 16% to 26% for 2025 [19] - Hezhong China reported a 10.24% decrease in January consolidated revenue [20] Group 7 - Zhongjian Technology plans to invest 30 million yuan in a new fund focused on new energy [22] - Kanda New Materials intends to invest 646 million yuan in a new production project [23] - Yuegui Co.'s subsidiary obtained a mining license [25] Group 8 - TBG Technology plans to invest 1.53 billion yuan in a new project [27] - Xiexin Integration stated it currently lacks production capacity in the "space photovoltaic" sector [28] - Shibao Testing's controlling shareholder plans to transfer 8.5% of the company's shares [29] Group 9 - TeBao Bio reported a 31.18% increase in revenue and a 25.39% increase in net profit for 2025 [30] - Guoke Tiancai reported a 14.73% increase in revenue and a 17.94% increase in net profit for 2025 [31] - Miaokelando signed a memorandum with SADAFCO to explore the children's cheese snack market in Saudi Arabia [32] Group 10 - Tangrenshen reported a 25.6% decrease in January sales revenue [33] - Northeast Securities received approval to establish a subsidiary in Hong Kong [34] - Yiyi Co. terminated its asset acquisition plan due to changes in the target company's performance [35] Group 11 - Wushang Group's major shareholder plans to reduce their stake by up to 3% [36] - Weigang Technology's shareholder plans to reduce their stake by up to 2.98% [37] - Yutong Technology plans to acquire 51% of Huayan Technology for 449 million yuan [38] Group 12 - Huasan Pharmaceutical's shareholder plans to reduce their stake by up to 3% [39] - Runbei Hangke's major shareholder plans to reduce their stake by up to 3% [41] - Huada Technology plans to acquire 100% of Huayi Microelectronics for 2.996 billion yuan [42] Group 13 - ST Lifang's stock will resume trading after completing self-inspection work [43]

Core Viewpoint - Yunnan Baiyao Group Co., Ltd. held its first board meeting of 2026 on February 10, 2026, where several key resolutions were passed to enhance production capacity and organizational structure, as well as appoint new executives to support the company's strategic goals [1][3][5]. Group 1: Project Approvals - The board approved the construction of the second phase of the oral liquid project at Wenshan Company with a total investment budget of 137.36 million yuan to meet the growing market demand for products like Qihuo Liquid [1]. - The board also approved the 2026 organizational structure plan to strengthen the implementation of strategic planning and operational goals [3]. Group 2: Executive Appointments - The board appointed Dong Ming as the CEO, Qian Yinghui as the board secretary, and Li Mengjue as the securities affairs representative, with a term of three years [5]. - Additionally, the board appointed several senior management personnel, including Li Hongshen, Li Shengli, He Tao, and Chen Shi as senior vice presidents, and Ma Jia as the financial director [8]. Group 3: Personnel Changes - Li Jin will no longer serve as a senior management member due to reaching the legal retirement age, and the company expressed gratitude for his contributions during his tenure [10][11]. - The company also announced the hiring of Zhu Zhaoyun as the strategic scientist for traditional Chinese medicine and Zhang Ning as the chief scientist to enhance its modern research and development capabilities [21].

Core Viewpoint - Yunnan Baiyao (000538.SZ) announced the construction of a second-phase project for oral liquid products to enhance production capacity and meet the growing market demand, aligning with the company's strategic goal of developing major product lines [1] Group 1 - The total investment budget for the new project is 137.36 million yuan [1] - The project aims to support the production of strategic large varieties within the group [1] - The initiative is part of the company's strategy to create a series of major single products [1]

Group 1 - The company conducted a telephone survey with institutional investors on January 22, 2026, discussing key issues such as drug development, subsidiary operations, health product channels, and dividend policies [1] - The company is making steady progress in clinical research for key drug products, including studies on diabetes foot, bone pain, and other areas, which will lay the foundation for expanding application scenarios [2] - The company plans to continue promoting existing product development while selectively extending external projects to complete its product matrix [2] Group 2 - The provincial pharmaceutical company will implement a "double rise and double drop" strategy, focusing on stabilizing existing hospital and distribution market shares while expanding non-drug businesses and new specialty pharmacies to cultivate new growth points [3] - The company aims to enhance operational efficiency by optimizing supply chain management and improving accounts receivable and inventory structures [3] Group 3 - In the health product sector, the company achieved significant breakthroughs in online channels in 2025, with a notable increase in product awareness and sales through strategic partnerships with e-commerce platforms [4] - The company’s toothpaste maintained the top market share in the domestic channel in the first half of 2025, and its anti-hair loss shampoo ranked first on Tmall during the "618" shopping festival [4] Group 4 - The company announced a high dividend policy for 2024, with a total cash dividend of approximately 4.279 billion yuan, representing 90.09% of the net profit attributable to shareholders [5] - For the first half of 2025, the company plans to distribute a cash dividend of 1.818 billion yuan, which is 50.05% of the net profit for that period [5] Group 5 - The strategic layout of the company in drug research, subsidiary operations, channel expansion, and shareholder returns is becoming clearer, with ongoing product development and supply chain optimization expected to strengthen its industry position [6] - The high dividend policy reflects the company's commitment to long-term returns for investors [6]

Group 1: Product Development and Clinical Research - The pharmaceutical division is focusing on the secondary development of key products, including clinical studies on Yunnan Baiyao (powder and capsules) for diabetic foot and bone pain, and Gongxue Ning capsules for treating abnormal uterine bleeding [2][3] - Recent clinical research results show Gongxue Ning capsules effectively reduce post-abortion vaginal bleeding and complications, with good overall safety [3] - The Qi Xue Kang oral solution is undergoing multi-center clinical studies for hypertension, with the first patient enrolled successfully [3] Group 2: Business Strategy and Market Expansion - The provincial pharmaceutical company aims to enhance market share in existing hospitals and distribution channels through a "double rise and double drop" strategy, focusing on non-drug businesses and new specialty pharmacies [4] - Efforts will be made to optimize supply chain management and improve accounts receivable and inventory structure, aiming for a patient-centered healthcare ecosystem [4] Group 3: Online Sales Performance - The pharmaceutical division's O2O sales increased by over 20% in the first half of 2025, with significant online marketing efforts boosting product awareness and sales [6] - During the 2025 "618" shopping festival, Yunnan Baiyao toothpaste ranked first in the domestic market share across all channels [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company plans to distribute a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7][8] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares will be distributed, amounting to 1.82 billion CNY, with special dividends accounting for 50.05% of the net profit for that period [8]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of CNY 4.751 billion, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year growth of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] Group 2: Online Sales and Marketing - The pharmaceutical business group expanded its online market, with O2O sales increasing by over 20% year-on-year [3] - During the 2025 "618" shopping festival, the company’s main products ranked significantly higher on the regular medicine list [3] - E-commerce platforms attracted 48.45 million visitors, resulting in 3.54 million consumers and generating a GMV of CNY 254 million [3] Group 3: Health Products Strategy - The health products group aims to become a leader in high-quality health lifestyle products, focusing on oral care and hair care [4] - Continuous enhancement of oral product advantages and rapid scaling of hair care business are key objectives for the second half of the year [4] Group 4: Nuclear Medicine Development - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received clinical trial approval, with 12 patients enrolled in Phase I trials [5] Group 5: Traditional Chinese Medicine Resource Development - The Chinese medicine resource group focuses on Yunnan's local medicinal materials, achieving significant results through collaborative efforts [6] - The establishment of 14 seed source bases and the completion of 90% of the annual target for quality seed promotion [6] - The digital cloud medicine platform achieved a transaction volume exceeding CNY 1 billion, with 18,000 registered farmers [6] Group 6: Future Directions for Provincial Pharmaceutical Company - The provincial pharmaceutical company plans to enhance market share in existing hospitals and distribution channels while exploring new growth areas [8] - Strategies include optimizing supply chain management and improving accounts receivable and inventory structure [8]

Group 1: Marketing and Sales Performance - In the first half of 2025, the pharmaceutical business group achieved over 20% year-on-year growth in O2O sales, leveraging platforms like Douyin and Xiaohongshu for extensive content marketing [2][3] - Online sales reached a GMV of 254 million CNY, with 48.45 million visitors and 3.54 million consumers driven to e-commerce platforms [3] - The company’s strategic partnership with JD Health significantly improved the ranking of its main products during the 2025 618 shopping festival [3] Group 2: Traditional Chinese Medicine (TCM) Resource Development - The TCM resource business group generated 914 million CNY in external revenue in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [4] - The group implemented a "six unifications" operational model to enhance the TCM supply chain, focusing on unified planting, sourcing, standards, processing, sales, and management [4] Group 3: Research and Development Progress - The company is advancing 16 major TCM projects, with 37 ongoing initiatives, focusing on secondary development and innovative drug creation [6] - Clinical trials for key products like Qixuekang and Gongxuening are progressing, with significant milestones achieved in various phases of testing [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company announced a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.16 billion CNY, which represents 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares was distributed, amounting to 1.82 billion CNY, which is 50.05% of the net profit for that period [8] Group 5: Digital Transformation Initiatives - The company is implementing a digital development plan (2022-2026) that integrates data and AI across key operational areas, enhancing efficiency and innovation [9][10] - A self-developed marketing operations platform has improved channel efficiency, reducing manual processing workload by 30% and eliminating 60,000 paper documents annually [9] - The digitalization of the TCM supply chain has significantly reduced transaction times from one day to mere minutes, enhancing overall operational efficiency [11]

Group 1: Health Products Business Performance - In the first half of 2025, the health products segment achieved revenue of 3.442 billion CNY, a year-on-year growth of 9.46% [2] - The segment focuses on a full-channel operation strategy, enhancing offline distribution and increasing online promotion efforts [2] - Key products include oral care toothpaste, which maintains a leading position, and hair care brand Yangyuanqing, which continues to grow driven by online sales [2][4] Group 2: Pharmaceutical Business Performance - The pharmaceutical segment reported a main business revenue of 4.751 billion CNY in the first half of 2025, with a year-on-year increase of 10.8% [5] - Sales of Yunnan Baiyao aerosol exceeded 1.453 billion CNY, showing a significant growth of over 20.9% [5] - Other traditional Chinese medicine products also saw notable growth, with sales of Qianling Jianpi Granules surpassing 100 million CNY and Pudilan Anti-inflammatory Tablets nearing 100 million CNY [5] Group 3: Traditional Chinese Medicine Resource Business - The traditional Chinese medicine resource segment generated external revenue of 914 million CNY in the first half of 2025, reflecting a year-on-year growth of approximately 6.3% [6] - The segment implements a "six unifications" operational model to enhance the traditional Chinese medicine industry chain [7] Group 4: R&D and Innovation Progress - The company emphasizes innovation-driven development, focusing on both traditional Chinese medicine and innovative drugs [8] - In the first half of 2025, the company initiated phase III clinical trials for the prostate cancer diagnostic nuclear drug project INR101, with 60 subjects enrolled [9] - The innovative drug project INR102 for prostate cancer treatment received clinical trial approval, and phase I trials have commenced [9] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of 11.85 CNY per 10 shares, totaling approximately 2.164 billion CNY [10] - The total cash dividend for 2024, including special dividends, amounted to 4.279 billion CNY, representing 90.09% of the net profit attributable to shareholders [10] - In the first half of 2025, the company distributed a cash dividend of 10.19 CNY per 10 shares, totaling 1.818 billion CNY, which accounted for 50.05% of the net profit for that period [10]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical business group achieved a main business revenue of 4.751 billion yuan, a year-on-year increase of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded 1.453 billion yuan, with a significant year-on-year growth of over 20.9% [2] - Other core products, including Yunnan Baiyao plaster and capsules, also saw notable growth, contributing to the overall revenue increase [2] - Plant-based products, such as Qixue Kang oral liquid, reached sales of 202 million yuan, with a year-on-year growth of approximately 116.2% [2] Group 2: Health Product Channel Development - The company has established a comprehensive national sales team for health products, maintaining a leading market share in Yunnan Baiyao toothpaste [4] - Continuous optimization of the entire channel has strengthened traditional offline advantages while also focusing on emerging retail formats like instant retail and community group buying [4] Group 3: Traditional Chinese Medicine Cultivation Achievements - The company has implemented a precise research and transformation model for seed innovation, achieving coverage of ten major Yunnan medicinal sources [5] - The area of high-quality seed promotion has reached 90% of the annual target, with significant progress in the construction of "Yun Medicine Seed Valley" [5] - Over 7,000 acres of GAP management have been added for various medicinal herbs, integrating low-altitude economy and IoT technology [5] Group 4: Online Sales Performance - The pharmaceutical business group has expanded its online market, with O2O sales increasing by over 20% year-on-year [6] - During the 2025 "618" shopping festival, the company achieved a GMV of 254 million yuan through e-commerce platforms, attracting 48.45 million visitors [7] - Yunnan Baiyao toothpaste maintained the top market share in the domestic channel, while Yangyuan Qing ranked first in Tmall for anti-hair loss shampoo [7] Group 5: Nuclear Medicine Research Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 60 subjects enrolled [8] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled [8]

Group 1: Pharmaceutical Business Performance - In the first half of 2025, the pharmaceutical segment achieved a revenue of CNY 4.751 billion, representing a year-on-year growth of 10.8% [2] - Sales revenue of Yunnan Baiyao aerosol exceeded CNY 1.453 billion, with a significant year-on-year increase of over 20.9% [2] - Other traditional Chinese medicine products showed remarkable growth, with sales of Canling Jianpi Granules exceeding CNY 100 million and Pudilan Anti-inflammatory Tablets nearing CNY 100 million [2] - Plant-based products, such as Qixue Kang Oral Liquid, reached sales of CNY 202 million, with a year-on-year growth of approximately 116.2% [2] Group 2: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project has initiated Phase III clinical trials, with 32 research centers established and 22 activated, enrolling 60 subjects [3] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with Phase I trials underway and 12 patients enrolled for Phase II trials [3] Group 3: Health Products Business Performance - The health products segment reported a revenue of CNY 3.442 billion in the first half of 2025, reflecting a year-on-year growth of 9.46% [4] - The segment focuses on a full-channel operation strategy, enhancing offline distribution capabilities and increasing online channel investments [4] - The oral care category, particularly gum care toothpaste, maintains and gradually expands its leading advantage, while anti-sensitivity toothpaste shows breakthrough growth [4] Group 4: Online Sales Performance - The pharmaceutical segment's online sales increased by over 20% year-on-year, with a GMV of CNY 254 million generated from 4.845 million visitors [5] - Yunnan Baiyao toothpaste holds the top market share in the domestic all-channel market, while Yangyuanqing shampoo ranked first in Tmall's domestic anti-hair loss category during the 2025 "618" shopping festival [5] Group 5: Dividend Distribution - For the 2024 fiscal year, the company distributed a cash dividend of CNY 11.85 per 10 shares, totaling CNY 2.164 billion [6] - The total cash dividend for 2024, including special dividends, amounted to CNY 23.98 per 10 shares, representing 90.09% of the net profit attributable to shareholders [7] - In the first half of 2025, the company distributed a cash dividend of CNY 10.19 per 10 shares, totaling CNY 1.818 billion, with special dividends accounting for 50.05% of the net profit for the period [7]